LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis

被引:28
|
作者
Shou, Jixin [1 ]
Gao, Haidong [1 ]
Cheng, Sen [1 ]
Wang, Bingbing [1 ]
Guan, Haibo [1 ]
机构
[1] Zhengzhou Univ, Dept Neurosurg, Affiliated Hosp 5, 3 Kangfu Front St, Zhengzhou 450052, Henan, Peoples R China
关键词
Glioblastoma; HOXA-AS2; miR-885-5p; RBBP4; Carcinogenesis; CELL-PROLIFERATION; NONCODING RNAS; CANCER; INVASION; GROWTH; ANGIOGENESIS; MIGRATION; METASTASIS; MECHANISMS; EXPRESSION;
D O I
10.1186/s12935-020-01690-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLncRNA HOXA-AS2 has been found in the literature to deteriorate glioblastoma. However, its regulatory mechanism is yet to be fully investigated. Our study focused chiefly on the interaction and role of the HOXA-AS2/miR-885-5p/RBBP4 axis in the development of glioblastoma.MethodsqRT-PCR analysis was performed to detect the expression of lncRNA, miRNA and mRNA in glioblastoma tissues and cells. Dual-luciferase assay, RIP assay and RNA pull-down assay were later carried out to reveal the interactions among HOXA-AS2, miR-885-5p and RBBP4. After that, CCK-8 assay, BrdU assay, nude mice xenografting assay, western blot assay, and flow cytometry were carried out to analyze the effect of the HOXA-AS2/miR-885-5p/RBBP4 axis on glioblastoma samples.ResultsHOXA-AS2 and RBBP4 were found to be overexpressed in glioblastoma. Experimental results showed that HOXA-AS2 and RBBP4 contributed to the tumorigenesis of glioblastoma cells. However, miR-885-5p was observed to be downregulated in glioblastoma. Findings also indicated that HOXA-AS2 could negatively regulate miR-885-5p, thereby enhancing RBBP4 expression.ConclusionOverall, HOXA-AS2 promoted the tumorigenesis of glioblastoma by targeting and regulating miR-885-5p to induce the expression of RBBP4.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis
    Jixin Shou
    Haidong Gao
    Sen Cheng
    Bingbing Wang
    Haibo Guan
    Cancer Cell International, 21
  • [2] LncRNA HOXA-AS2 facilitates prostate cancer progression by inhibiting miR-885-5p to upregulate KDM5B
    Yang, Zhi
    Zhang, Fan
    Cai, Kai
    Xu, Jianxin
    KIDNEY & BLOOD PRESSURE RESEARCH, 2023, 48 (01): : 45 - 55
  • [3] LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis
    Lin, Ligang
    Lin, Da
    Jin, Lingjiang
    Wang, Junyou
    Lin, Zheng
    Zhang, Shuai
    Lin, Gaojun
    GENETICS RESEARCH, 2022, 2022
  • [4] LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis
    Xiao, Shangwen
    Song, Bin
    BIOSCIENCE REPORTS, 2020, 40
  • [5] LncRNA HOXA-AS2 Facilitates Tumorigenesis and Progression of Papillary Thyroid Cancer by Modulating the miR-15a-5p/HOXA3 Axis
    Jiang, Liangfeng
    Wu, Zhiming
    Meng, Xingcheng
    Chu, Xiufeng
    Huang, Hongjun
    Xu, Chaoyang
    HUMAN GENE THERAPY, 2019, 30 (05) : 618 - 631
  • [6] LncRNA HOXA-AS3 promotes the malignancy of glioblastoma through regulating miR-455-5p/USP3 axis
    Chen, Wanghao
    Li, Qiaoyu
    Zhang, Guilong
    Wang, Hong
    Zhu, Zhihan
    Chen, Lukui
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (20) : 11755 - 11767
  • [7] miR-885-5p Inhibits Invasion and Metastasis in Gastric Cancer by Targeting Malic Enzyme 1
    Jiang, Zhaoyu
    Cui, Huaiping
    Zeng, Shujie
    Li, Leping
    DNA AND CELL BIOLOGY, 2021, 40 (05) : 694 - 705
  • [8] LncRNA HOXA-AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR-372
    Wang, Yanli
    Shao, Wenjing
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [9] Contribution of PKS plus Escherichia coli to colon carcinogenesis through the inhibition of exosomal miR-885-5p
    He, Xiaoming
    Ren, Enbo
    Dong, Lujia
    Yuan, Pengfei
    Zhu, Jiaxin
    Liu, Dechun
    Wang, Jianguang
    HELIYON, 2024, 10 (18)
  • [10] MiR-885-5p promotes gastric cancer proliferation and invasion through regulating YPEL1
    Li, S.
    Sun, M-Y
    Su, X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (18) : 7913 - 7919